Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-27
2008-12-09
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S202000
Reexamination Certificate
active
07462630
ABSTRACT:
The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment:wherein, A represents CH═CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V—W represents C═C, etc., n represents 0 to 3, Y1 represents O etc., B represents —(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents —CO—, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, —COR18a, —COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.
REFERENCES:
patent: 4297346 (1981-10-01), Rips et al.
patent: 2004/0167118 (2004-08-01), Yamamoto et al.
patent: 2005/0009814 (2005-01-01), Iwayama et al.
patent: 0 682 015 (1995-11-01), None
patent: 0 710 661 (1996-05-01), None
patent: 0 739 881 (1996-10-01), None
patent: 8-3135 (1996-01-01), None
patent: 8-3155 (1996-01-01), None
patent: 8-291142 (1996-11-01), None
patent: WO 95/11238 (1995-04-01), None
patent: WO 99/00376 (1999-01-01), None
patent: WO 99/37296 (1999-07-01), None
patent: WO 00/01375 (2000-01-01), None
patent: WO 02/22588 (2002-03-01), None
Timmerman et al. “Preparation of piperidine . . . ” CA 126:18791 (1996).
Vega-Hernandez et al. “Down regulation of N-rype . . . ” Cell. and Mol. Neurobiology v.22(2) (2002) p. 185-190.
Sutton et al. “Gabapentin inhibits . . . ” Br. J. Pharm. v.135 (2002)p. 257-265.
R.S. Kamel, et al.,Clinical Chemistry, vol. 25, No. 12, pp. 1997-2002 (1979).
U.S. Appl. No. 10/911,633, filed Aug. 5, 2004, Iwayama, et al.
Fujita Shinichi
Iwayama Satoshi
Koganei Hajime
Moki Keiko
Niwa Seiji
Ajinomoto Co. Inc.
Chang Celia
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Diarylalkene derivatives and novel diarylalkane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diarylalkene derivatives and novel diarylalkane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diarylalkene derivatives and novel diarylalkane derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021692